In Germany, Prof. Dr. Umut Şahin evaluated the decision of the US Food and Drug Administration (FDA) for emergency use of the vaccine to CNN International. “This is a very high quality milestone,” Şahin said. I’m really happy we had such a good meeting and the FDA allowed the vaccine. Thus, we can make our vaccine available to the US population, ”he said.
Phase2 work begins on December 25!
PROVEN TO BE 95 PERCENT EFFECTIVE
In the clinical trials conducted in the coronavirus vaccine developed by BioNTech and Pfizer, with 40 thousand volunteers, it was stated that the vaccine was 95 percent effective. “We expect those who are vaccinated with the highest quality results to have a much lower risk of hospitalization. This means we expect a lower risk of hospitalization in the US. Of course, we will not have a direct impact on the spread of the pandemic in the next few months, as we need to reach a large portion of the population to reduce the pace of the epidemic.